Cancer pharmacogenomics, adoption by oncologists and patient benefit.

  title={Cancer pharmacogenomics, adoption by oncologists and patient benefit.},
  author={Lynn G. Dressler and Allison M Deal and Jai N Patel and Janell M. Markey and Marcia van Riper and Ping Liao},
  journal={Personalized medicine},
  volume={11 2},
AIM The study aim was to understand physician experience and factors influencing the adoption of cancer pharmacogenomic (caPGx) testing by oncologists practicing in academic and nonacademic settings. METHOD Anonymous paper surveys were distributed to oncologists practicing in North Carolina (USA). RESULTS Although 98% of oncologists see promise in utilizing PGx tests in their practice, few were comfortable with their knowledge (33%) or interpreting test results (37%). At one site, the… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.


Publications referenced by this paper.
Showing 1-10 of 38 references

An evaluation of pharmacists ’ expectations towards

  • S deDenus, N Letarte, T Hurlimann
  • 2013

Knowledge , attitudes and education of pharmacists regarding pharmacogenetic testing

  • MW Roederer, M VanRiper, JM Valgus
  • Pers . Med .
  • 2012

Similar Papers

Loading similar papers…